4.3 Review

Antiglaucoma medications: A review of safety and tolerability issues related to their use

期刊

CLINICAL THERAPEUTICS
卷 22, 期 2, 页码 167-208

出版社

ELSEVIER
DOI: 10.1016/S0149-2918(00)88478-7

关键词

glaucoma; adverse effects; beta-adrenergic-receptor antagonists; alpha(2)-adrenergic-receptor agonists; cholinergic agents; prostaglandin analogues; carbonic anhydrase inhibitors

向作者/读者索取更多资源

Background: Much experience has been gained with the use of older classes of antiglaucoma agents-topical beta-adrenergic-receptor antagonists, nonselective adrenergic-receptor agonists, oral carbonic anhydrase inhibitors, and cholinergic agents. In the past decade, new drugs and classes of drugs used to treat glaucoma have become available, including topical carbonic anhydrase inhibitors, prostaglandin analogues, and alpha(2)-adrenergic-receptor agonists. Extensive community-based use of antiglaucoma medications has led to an increased understanding of the acute and long-term safety and tolerability issues associated with their use. Objective: This paper reviews the side effects associated with the various classes of topical antiglaucoma drugs, with a particular focus on long-term safety issues.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据